Investor discloses 22% stake in ENvue Medical
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026. On January 14, 2026, he purchased 240,000 shares in an open market transaction at an average price of $2.67 per share, using personal funds totaling approximately $640,737.85. He states the shares were acquired for investment purposes and that he may buy more or sell some in the future, but reports no current plans for corporate actions and no contracts or arrangements with others regarding the issuer’s securities.
Insights
Large 22% stake disclosed by individual investor using personal funds.
Christian Michael Glibert now reports beneficial ownership of 240,000 ENvue Medical common shares, or about 22.05% of the company. The entire position was acquired in a single open market purchase on January 14, 2026 at an average price of $2.67 per share.
The filing describes the purchase as being for investment purposes, funded with approximately $640,737.85 of personal capital. It also notes there are no contracts or understandings with other parties regarding ENvue Medical’s securities, and no present plans for transactions such as mergers, asset sales, or changes in control.
Future changes in Glibert’s holdings would be reflected in subsequent beneficial ownership filings if thresholds are met, while ENvue’s total shares outstanding are stated as 1,088,192 as of February 2026, providing context for the scale of this stake within the company’s equity base.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Christian Michael Glibert’s Schedule 13D filing reveal about ENvue Medical (FEED)?
What percentage of ENvue Medical (FEED) does Christian Michael Glibert now own?
AI-generated analysis. How Rhea-AI works. Not financial advice.